
Efficacy Rate80%
Studies3
Participants2,514
StatusAvailable
PT-141
Bremelanotide
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist specifically designed to treat hypoactive sexual desire disorder in premenopausal women. Unlike other sexual health treatments, PT-141 works through the central nervous system to enhance sexual desire and arousal rather than affecting blood flow or hormones.
Complete Research Database
Clinical Efficacy by Dose
15%
Placebo
25%
1.25 mg
35%
1.75 mg
42%
10 mg
Placebo
15%
1.25 mg
25%
1.75 mg
35%
10 mg
42%
Source: Clinical research data
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.